Page - 44 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Dawidczyketal. Nanomedicines for cancer therapy therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 291–317. doi: 10.1016/j.bbagen.2011.07.016 Davis, M. E., Chen, Z., and Shin, D. M. (2008). Nanoparticle therapeutics: an emergingtreatmentmodality forcancer.Nat.Rev.DrugDiscov.7,771–782.doi: 10.1038/nrd2614 Dawidczyk,C.M.,Kim,C., Park, J.H.,Russell, L.M., Lee,K.H., Pomper,M.G., etal. (2014).State-of-the-art indesignrules fordrugdeliveryplatforms: lessons learned fromFDA-approved nanomedicines. J. Control. Release 187, 133–144. doi:10.1016/j.jconrel.2014.05.036 Dechantsreiter,M.A., Planker, E.,Matha, B., Lohof, E.,Holzemann,G., Jonczyk, A., et al. (1999).N-methylated cyclicRGDpeptides as highly active and selec- tive alpha(v)beta(3) integrin antagonists. J. Med. Chem. 42, 3033–3040. doi: 10.1021/jm970832g Dill, K., Lin, M., Poteras, C., Fraser, C., Hafeman, D. G., Owicki, J. C., et al. (1994).Antibody-antigenbindingconstantsdeterminedinsolution-phasewith the thresholdmembrane-capture system - binding constants for antifluores- cein,anti-saxitoxin,andanti-ricinantibodies.Anal.Biochem.217,128–138.doi: 10.1006/abio.1994.1093 Di Pasqua, A. J., Miller, M. L., Lu, X. L., Peng, L., and Jay, M. (2012). Tumor accumulation of neutron-activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer mouse model. InorganicaChim.Acta393,334–336.doi:10.1016/j.ica.2012.06.016 Duncan, R. (2006). Polymer conjugates as anticancer nanomedicines.Nat. Rev. Cancer6,688–701.doi:10.1038/nrc1958 Erttmann,R.,Erb,N.,Steinhoff,A.,andLandbeck,G.(1988).Pharmacokineticsof doxorubicin inman:doseandscheduledependence. J.CancerRes.Clin.Oncol. 114,509–513.doi:10.1007/BF00391502 Fang, J., Nakamura, H., and Maeda, H. (2011). The EPR effect: unique fea- tures of tumor blood vessels for drug delivery, factors involved, and limita- tions and augmentation of the effect.Adv. DrugDeliv. Rev. 63, 136–151. doi: 10.1016/j.addr.2010.04.009 Fonge, H., Huang, H., Scollard, D., Reilly, R. M., and Allen, C. (2012). Influence of formulation variables on the biodistribution of multifunc- tional block copolymer micelles. J. Control. Release 157, 366–374. doi: 10.1016/j.jconrel.2011.09.088 Frese, K. K., andTuveson,D. A. (2007).Maximizingmouse cancermodels.Nat. Rev.Cancer7,645–658.doi:10.1038/nrc2192 Fuchs, S., andCoester, C. (2010). Protein-based nanoparticles as a drug delivery system:chances, risks,perspectives. J.DrugDeliv.Sci.Technol.20,331–342. Furger, K. A., Allan, A. L.,Wilson, S.M., Hota, C., Vantyghem, S. A., Postenka, C.O., et al. (2003). Beta(3) integrin expression increases breast carcinomacell responsivenesstothemalignancy-enhancingeffectsofosteopontin.Mol.Cancer Res.1,810–819. Gabizon,A.,Catane,R.,Uziely,B.,Kaufman,B., Safra,T.,Cohen,R., et al. (1994). Prolongedcirculation timeandenhancedaccumulation inmalignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.Cancer Res.54,987–992. Gabizon, A., Shmeeda,H., and Barenholz, Y. (2003). Pharmacokinetics of pegy- lated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet.42,419–436.doi:10.2165/00003088-200342050-00002 Gao, J. H., Chen, K., Xie, R. G., Xie, J., Yan, Y. J., Cheng, Z., et al. (2010). In vivo tumor-targeted fluorescence imaging using near-infrared non-cadmium quantumdots.Bioconjug.Chem.21,604–609.doi:10.1021/bc900323v Gao, X.H., Cui, Y. Y., Levenson, R.M., Chung, L.W.K., andNie, S.M. (2004). In vivo cancer targeting and imagingwith semiconductor quantumdots.Nat. Biotechnol.22,969–976.doi:10.1038/nbt994 Gill,P. S.,Wernz, J., Scadden,D.T.,Cohen,P.,Mukwaya,G.M.,VonRoenn, J.H., etal. (1996).RandomizedphaseIII trialof liposomaldaunorubicinversusdox- orubicin, bleomycin, andvincristine inAIDS-relatedKaposi’s sarcoma. J.Clin. Oncol.14,2353–2364. Giri, S., Trewyn, B.G., and Lin, V. S. Y. (2007).Mesoporous silica nanomaterial- based biotechnological and biomedical delivery systems. Nanomedicine 2, 99–111.doi:10.2217/17435889.2.1.99 Giri, S., Trewyn,B.G., Stellmaker,M.P., andLin,V. S. (2005). Stimuli-responsive controlled-releasedeliverysystembasedonmesoporoussilicananorodscapped withmagnetic nanoparticles.Angew. Chem. Int. Ed. Engl. 44, 5038–5044. doi: 10.1002/anie.200501819 Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., et al. (2012). Clinical pharmacologyof trastuzumabemtansine (T-DM1): anantibody-drug conjugate in development for the treatment ofHER2-positive cancer.Cancer Chemother.Pharmacol.69,1229–1240.doi:10.1007/s00280-011-1817-3 Greco,F., andVicent,M. J. (2009).Combination therapy:opportunities andchal- lenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv.Rev.61,1203–1213.doi:10.1016/j.addr.2009.05.006 Hainfeld, J. F., Slatkin, D.N., Focella, T.M., and Smilowitz, H.M. (2006). Gold nanoparticles: a new X-ray contrast agent. Br. J. Radiol. 79, 248–253. doi: 10.1259/bjr/13169882 Hamilton, A., Biganzoli, L., Coleman, R.,Mauriac, L., Hennebert, P., Awada, A., et al. (2002). EORTC 10968: a phase I clinical and pharmacokinetic study of polyethyleneglycol liposomaldoxorubicin (Caelyx,Doxil) at a 6-week interval in patients withmetastatic breast cancer. European organization for research andtreatmentofcancer.Ann.Oncol.13,910–918.doi:10.1093/annonc/mdf157 Hanahan,D.,andWeinberg,R.A.(2011).Hallmarksofcancer:thenextgeneration. Cell144,646–674.doi:10.1016/j.cell.2011.02.013 Harrington, K. J., Rowlinson-Busza, G., Syrigos, K. N., Abra, R.M., Uster, P. S., Peters,A.M.,etal. (2000). InfluenceoftumoursizeonuptakeofIn-111-DTPA- labelledpegylated liposomes inahumantumourxenograftmodel.Br. J.Cancer 83,684–688.doi:10.1054/bjoc.2000.1320 Hartmann,L.C.,Keeney,G. L., Lingle,W.L.,Christianson,T. J.H.,Varghese, B., Hillman,D.,etal. (2007).Folatereceptoroverexpressionisassociatedwithpoor outcomeinbreast cancer. Int. J.Cancer121,938–942.doi:10.1002/ijc.22811 Haubner,R.,Gratias,R.,Diefenbach,B.,Goodman,S.L., Jonczyk,A., andKessler, H. (1996). Structural and functional aspects of RGD-containing cyclic pen- tapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists. J.Am.Chem.Soc.118,7461–7472.doi:10.1021/ja9603721 Haun, J. B., Yoon, T. J., Lee, H., andWeissleder, R. (2010).Magnetic nanoparti- clebiosensors.Wiley Interdiscip.Rev.Nanome.Nanobiotechnol.2,291–304.doi: 10.1002/wnan.84 Helbok,A.,Rangger,C.,VonGuggenberg,E.,Saba-Lepek,M.,Radolf,T.,Thurner, G., et al. (2012).Targetingproperties of peptide-modified radiolabeled liposo- malnanoparticles.Nanomedicine8,112–118.doi:10.1016/j.nano.2011.04.012 Hilgenbrink, A. R., and Low, P. S. (2005). Folate receptor-mediated drug tar- geting: from therapeutics to diagnostics. J. Pharm. Sci. 94, 2135–2146. doi: 10.1002/jps.20457 Hoang, B., Lee, H., Reilly, R. M., and Allen, C. (2009). Noninvasive monitor- ing of the fate of in-111-labeled block copolymermicelles by high resolution and high sensitivityMicroSPECT/CT imaging.Mol. Pharm. 6, 581–592. doi: 10.1021/mp8002418 Holliger, P., andHudson,P. J. (2005).Engineeredantibody fragments and the rise of singledomains.Nat.Biotechnol.23,1126–1136.doi:10.1038/nbt1142 Hong, H., Yang, K., Zhang, Y., Engle, J. W., Feng, L., Yang, Y., et al. (2012). In vivo targeting and imaging of tumor vasculaturewith radiolabeled, antibody- conjugatednanographene.ACSNano6,2361–2370.doi:10.1021/nn204625e Hong, R. L., and Tseng, Y. L. (2001). Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 91, 1826–1833. doi: 10.1002/1097-0142(20010501)91:9<1826::AID- CNCR1203>3.0.CO;2-J Horcajada,P.,Gref,R.,Baati,T.,Allan,P.K.,Maurin,G.,Couvreur,P.,etal. (2012). Metal-organic frameworks in biomedicine. Chem. Rev. 112, 1232–1268. doi: 10.1021/cr200256v Hosotani, R., Kawaguchi,M.,Masui, T., Koshiba, T., Ida, J., Fujimoto, K., et al. (2002). Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation toMMP-2 activation and lymph nodemetastasis. Pancreas 25, e30–e35. doi: 10.1097/00006676-200208000-00021 Hsu,C.W.,Chang,Y.J.,Chang,C.H.,Chen,L.C.,Lan,K.L.,Ting,G.,etal.(2012). Comparativetherapeuticefficacyofrhenium-188radiolabeled-liposomeand5- fluorouracil inLS-174Thumancoloncarcinomasolidtumorxenografts.Cancer Biother.Radiopharm.27,481–489.doi:10.1089/cbr.2011.1158 Hu,M., andZhang,K. (2013).Theapplicationof aptamers in cancer research: an up-to-date review.FutureOncol.9,369–376.doi:10.2217/fon.12.201 Hu,Z.,Luo,F.,Pan,Y.,Hou,C.,Ren,L.,Chen,J., etal. (2008).Arg-Gly-Asp(RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide)micelle for targeted drugdelivery. J.Biomed.Mater.Res.A85,797–807.doi:10.1002/jbm.a.31615 Huang, F. Y. J., Lee, T. W., Kao, C. H. K., Chang, C. H., Zhang, X. N., Lee, W. Y., et al. (2011). Imaging, autoradiography, and biodistribution of Re- 188-labeledPEGylatednanoliposome inorthotopic gliomabearing ratmodel. CancerBiother.Radiopharm.26,717–725.doi:10.1089/cbr.2011.1052 Frontiers inChemistry | ChemicalEngineering August2014 |Volume2 |Article69 | 44